Evidence map›Paper›PMID 41038816›Full record

ReviewThe pharmacogenomics journal2025

An innovative model for pharmacogenomics critical results identification and intervention.

Ryley Uber, Vanessa A Hayduk, Alison Flango, Theron Ward, Leeann Webster, Eric A Wright

Abstract readReview
PubMed Publisher
In one paragraph

Review in The pharmacogenomics journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ryley UberCenter for Pharmacy Innovation and Outcomes, Geisinger, Danville, PA, USA. ruber@geisinger.edu.ORCID 0000-0003-0448-7584
Vanessa A HaydukCenter for Pharmacy Innovation and Outcomes, Geisinger, Danville, PA, USA.ORCID 0000-0002-1056-6038
Alison FlangoEnterprise Pharmacy, Geisinger, Danville, PA, USA.
Theron WardEnterprise Pharmacy, Geisinger, Danville, PA, USA.
Leeann WebsterEnterprise Pharmacy, Geisinger, Danville, PA, USA.ORCID 0009-0009-4465-224X
Eric A WrightCenter for Pharmacy Innovation and Outcomes, Geisinger, Danville, PA, USA.ORCID 0000-0003-1721-4104

Funding

Pennsylvania Department of Health (PDH) SAP# 4100088547
6 · The paper itself

Abstract

Pharmacogenomics (PGx) test results are returned variably across healthcare settings, which can lead to challenges particularly when results require immediate intervention to avoid adverse consequences. While several return of result models exist in literature, a standard-of-care has not been established. We propose a model to safely return PGx results in the context of scaled and sustained PGx testing: an institutional protocol to integrate new PGx results into patient care.

Indexed as

PharmacogeneticsPharmacogenomic TestingHumansPrecision Medicine

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.